Skip to main content

Basel is “probably the most productive life sciences location in the world”

| News

Basel is “probably the most productive life sciences location in the world”


Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Roche Tower in Basel (img: Mark Niedermann)

The association Interpharma has looked into the Swiss pharma cluster as part of a report and compared it with other international life sciences locations. The Basel Area is described in the report as the “leading pharma region of Switzerland”. According to information contained in the report, at a total of 24.5 billion Swiss francs, the area is responsible for generating two thirds of Switzerland’s pharma value added as a whole.

Numerous companies from the life sciences sector are located within the Basel Region. These include, for example, Novartis, Roche, Actelion, Bayer and Boehringer Ingelheim, among others. These companies not only cover the entire value chain of the pharmaceutical industry, but they are also active in the areas of medtech and biotech as well. According to the report, value added generated by the Basel Area pharma cluster has doubled in real terms over the past decade, with around 6,000 extra jobs having been created within the sector here as well. In 2018, a total of 32,000 people were employed in the life sciences sector in the Basel Area.

Companies located in the Basel Area are also highlighted in the report for being particularly innovative as well. The high intensity of research on the part of these firms is for example, reflected in the number of patent applications. In this context, in 2015, 108 patent applications were registered per million inhabitants in the pharma sector. The Basel pharma cluster, in tandem with Boston, therefore registered the most patent applications per million inhabitants in comparison with other pharma clusters. These top scores have even seen the Basel Region overtake life sciences locations such as the San Francisco Bay Area and Øresund in the area of pharma. According to René Buholzer, CEO of Interpharma, the Basel Region is “probably the most productive life sciences location in the world” overall.

The success of the Basel pharmaceutical sector is attributed to the favourable framework conditions, among other factors, in the report. Moreover, the presence of top-class colleges and universities such as the University of Basel and an offshoot of the Swiss Federal Institute of Technology in Zurich (ETH) also plays a significant role. Last but not least, the region’s proximity to Germany and France, to EuroAirport Basel-Mulhouse-Freiburg as well as to Switzerland’s Rhine ports is additionally highlighted.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.